ALF-201

N/A

Report date: 2026/05/26 20:00:28

Base Information

Drug NameALF-201
Drug Alias Name异体内皮祖细胞（EPCs）（呈诺再生医学科技）Allogeneic endothelial progenitor cells (Allife Medicine Tech)ALF201ALF-201iPSC EPCs +[6] 
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Somatic cell > Endothelial progenitor cell therapyCell and gene therapy > Cell therapy > Source of cells > iPSC-derived
Mechanisms of ActionCell replacements
TargetsNot applicable
Therapy Area/IndicationsIschemic StrokeIschemiaStroke
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Allife Medicine Tech Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesChengnuo Regenerative Medicine Technology (Zhuhai Hengqin New Area) Co LtdBeijing Allife Medicine Tech Co Ltd
Inactive CompaniesChengnuo Regenerative Medicine Technology (Beijing) Co Ltd
Active IndicationsIschemic StrokeIschemia
Inactive IndicationsStroke

Other Information

ATC CodeN/A
Related LinksN/A